Squarepoint
AXSM icon

Squarepoint’s Axsome Therapeutics AXSM Stock Holding History

Squarepoint’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$220K Buy
+900
New +$195K ﹤0.01% 4005
2026
Q1 		– Sell
-2,900
Closed -$530K – 4264
2025
Q4 		$530K Buy
2,900
+100
+4% +$14K ﹤0.01% 3167
2025
Q3 		$340K Hold
2,800
– – ﹤0.01% 3568
2025
Q2 		$292K Sell
2,800
-13,700
-83% -$1.45M ﹤0.01% 3713
2025
Q1 		$1.92M Buy
16,500
+9,400
+132% +$1.07M ﹤0.01% 2124
2024
Q4 		$601K Sell
7,100
-2,300
-24% -$212K ﹤0.01% 3575
2024
Q3 		$845K Buy
+9,400
New +$821K ﹤0.01% 2726

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Squarepoint's AXSM Position: Q2 2026 in Review

Squarepoint increased its Axsome Therapeutics (AXSM) stake by 35% in Q2 2026, buying an estimated $8.78M and bringing the position to 154,605 shares worth $37.8M. The position accounts for 0.04% of the portfolio, ranked #429.

Squarepoint first reported a position in AXSM in Q3 2017 and has held it in 20 quarters since. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Squarepoint held 154,605 shares of Axsome Therapeutics worth $37.8M as of Q2 2026.
  • Squarepoint bought 40,503 Axsome Therapeutics shares in Q2 2026, an estimated $8.78M.
  • Axsome Therapeutics made up 0.04% of Squarepoint's portfolio in Q2 2026, its #429 holding.
  • Squarepoint first reported a position in Axsome Therapeutics in Q3 2017 and has held it in 20 quarters since.
  • 506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Squarepoint's 13F filing for Q2 2026, filed 14 Aug 2026.